India

Bharat Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bharat Biotech Starts Human Trial of its Anti-COVID Vaccine at PGI Rohtak: Minister Vij

Lead Product(s): BBV152

Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2020

Details:

Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak.

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Zydus Starts Human Trials of ZyCoV-D, its COVID-19 Vaccine

Lead Product(s): ZyCoV-D

Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The Adaptive Phase I/II dose-escalation, the multi-centric study will assess the safety, tolerability and immunogenicity of the company's plasmid DNA vaccine, ZyCoV-D.

Bharat Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ICMR Partners with Bharat Biotech to Launch COVID-19 Vaccine

Lead Product(s): BBV152

Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: ICMR

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 06, 2020

Details:

For covaxin, Bharat Biotech has joined with the National Institute of Virology, part of the Indian Council of Medical Research. The company is separately developing COVID-19 vaccine candidates in collaboration with Thomas Jefferson University and the University of Wisconsin.

Bharat Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bharat Biotech Develops India’s First DCGI-Approved Vaccine Candidate, Gets Nod for Human Trials

Lead Product(s): BBV152

Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Bharat Biotech

Bharat Biotech Starts Human Trial of its Anti-COVID Vaccine at PGI Rohtak: Minister Vij

Zydus Cadila

Zydus Starts Human Trials of ZyCoV-D, its COVID-19 Vaccine

Bharat Biotech

ICMR Partners with Bharat Biotech to Launch COVID-19 Vaccine

Bharat Biotech

Bharat Biotech Develops India’s First DCGI-Approved Vaccine Candidate, Gets Nod for Human Trials